Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Long-Term Study of JTE-052 (delgocitinib) Ointment in Japanese Infants With Atopic Dermatitis
jRCT2080225316Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of delgocitinib in atopic dermatitis (AD) (2 arms), sponsored by Japan Tobacco. Primary endpoints: Safety and tolerability of delgocitinib ointment and Systemic exposure to delgocitinib. Started Aug 2020; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080225316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225316.